![]() |
Name |
25-Norisopropyl-9,19-cyclolanostan-22-en-24-one, 3-acetoxy-24-phenyl-4,4,14-trimethyl-
|
Molecular Formula | C35H48O3 | |
IUPAC Name* |
[7,7,12,16-tetramethyl-15-[(E)-5-oxo-5-phenylpent-3-en-2-yl]-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl] acetate
|
|
SMILES |
CC(/C=C/C(=O)C1=CC=CC=C1)C2CCC3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC(=O)C)C)C
|
|
InChI |
InChI=1S/C35H48O3/c1-23(12-13-27(37)25-10-8-7-9-11-25)26-16-18-33(6)29-15-14-28-31(3,4)30(38-24(2)36)17-19-34(28)22-35(29,34)21-20-32(26,33)5/h7-13,23,26,28-30H,14-22H2,1-6H3/b13-12+
|
|
InChIKey |
GRLIQRYEGDHYJO-OUKQBFOZSA-N
|
|
Synonyms |
25-Norisopropyl-9,19-cyclolanostan-22-en-24-one, 3-acetoxy-24-phenyl-4,4,14-trimethyl-; 3a,6,6,12a-Tetramethyl-1-[(2E)-1-methyl-4-oxo-4-phenyl-2-butenyl]tetradecahydro-1H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl acetate #
|
|
CAS | NA | |
PubChem CID | 5373661 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 516.8 | ALogp: | 9.5 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 43.4 | Aromatic Rings: | 6 |
Heavy Atoms: | 38 | QED Weighted: | 0.207 |
Caco-2 Permeability: | -4.966 | MDCK Permeability: | 0.00001660 |
Pgp-inhibitor: | 0.899 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.929 |
Blood-Brain-Barrier Penetration (BBB): | 0.044 | Plasma Protein Binding (PPB): | 99.98% |
Volume Distribution (VD): | 1.282 | Fu: | 1.80% |
CYP1A2-inhibitor: | 0.025 | CYP1A2-substrate: | 0.16 |
CYP2C19-inhibitor: | 0.094 | CYP2C19-substrate: | 0.836 |
CYP2C9-inhibitor: | 0.112 | CYP2C9-substrate: | 0.479 |
CYP2D6-inhibitor: | 0.062 | CYP2D6-substrate: | 0.344 |
CYP3A4-inhibitor: | 0.334 | CYP3A4-substrate: | 0.513 |
Clearance (CL): | 6.423 | Half-life (T1/2): | 0.012 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.212 |
Drug-inuced Liver Injury (DILI): | 0.033 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.245 | Maximum Recommended Daily Dose: | 0.776 |
Skin Sensitization: | 0.071 | Carcinogencity: | 0.039 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.113 |
Respiratory Toxicity: | 0.945 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001582 | ![]() |
0.551 | D04XPW | ![]() |
0.273 | ||
ENC001833 | ![]() |
0.424 | D0TB8C | ![]() |
0.270 | ||
ENC002119 | ![]() |
0.375 | D0R2KY | ![]() |
0.269 | ||
ENC003874 | ![]() |
0.356 | D06CWH | ![]() |
0.265 | ||
ENC002686 | ![]() |
0.347 | D03MTN | ![]() |
0.260 | ||
ENC003457 | ![]() |
0.338 | D0X7XG | ![]() |
0.258 | ||
ENC001721 | ![]() |
0.338 | D06CNP | ![]() |
0.252 | ||
ENC005527 | ![]() |
0.335 | D06PSS | ![]() |
0.250 | ||
ENC005020 | ![]() |
0.329 | D0V2JK | ![]() |
0.250 | ||
ENC001949 | ![]() |
0.327 | D02CJX | ![]() |
0.248 |